Abstract
HER2 / neu is a potential antigen candidate for immunotherapy because of its correlation to a poor prognosis and high expressions in many kinds of epithelial tumours. Especially in the colorectal carcinomas, the higher expression of HER2 / neu is recognized in metastatic regions as well as in primary sites. Several CTL epitopes restricted by HLA-A2.1 and -A3 were identified so far, however epitopes restricted by HLA-A24, that is one of the most common allele in Japanese and Caucasians, have not been identified. In this paper, we showed identification of a CTL epitope peptide of HER2 / neu restricted by HLA-A24. HLA-A24 binding peptides selected by an analysis based on HLA-A24 binding motifs were determined for their binding affinities to HLA-A24 molecules. The peptide with a sequence of RWGLLLALL (position 8–16) named HE1 showed the highest affinity. We induced CTLs from CD8+ cells of HLA-A24 healthy donors by stimulation with HE1-pulsed autologous dendritic cells. The CTLs showed cytotoxic activity against not only the peptide-pulsed target cells but also HLA-A24 colorectal tumour cell lines that endogenously overexpressed HER2 / neu. The antigen-specificity was confirmed by cold target inhibition assay using HE1-pulsed target cells. In summary, HER2 / neu peptide, RWGLLLALL, may contribute to the induction of antitumour immunity with the peptide-based immunotherapy for the colorectal carcinomas. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Albino AP, Jaehne J, Altorki N, Blundell M, Urmacher C, Lauwers G, Niedzwiecki D and Kelsen DP (1995) Amplification of HER-2 / neu gene in human gastric adenocarcinomas: colleration with primary site. Eur J Surg Oncol 21: 56–60
Bacus SS, Stancovski I, Huberman E, Chin D, Hurwitz E, Mills GB, Ullrich A, Sela M and Yarden Y (1992) Tumor-inhibitory monoclonal antibodies to the HER-2 / neu receptor induce differentiation of human breast cancer cells. Cancer Res 52: 2580–2589
Baselga J, Norton L, Albanell J, Kim YM and Mendelsohn J (1998) Recombinant humanized anti-HER-2 / neu antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxolubicin against HER-2 / neu overexpressing human breast cancer xenographts. Cancer Res 58: 2825–2831
Boon T (1993) Tumor antigens recognized by cytotoxic T lymphocytes: Present perspectives for specific immunotherapy. Int J Cancer 54: 177–180
Boon T and van der Bruggen P (1996) Human tumor antigen recognized by T lymphocytes. J Exp Med 183: 725–729
Brichard V, Van Pel A, Wolfel T, Wolfel C, De-Plaen E, Lethe B, Coulier P and Boon T (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178: 489–495
Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L and Brugger W (1998) Her-2 / neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific T lymphocytes. Cancer Res 58: 732–736
Celis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chesnut RW, Grey HM, Sette A and Serra HM (1994) Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91: 2105–2109
Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A and Ullrich A (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132–1139
Date Y, Kimura A, Kato H and Sasazuki T (1996) DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese. Tissue Antigens 47: 93–101
Fisk B, Chesak B, Ioannides MG, Wherton JT and loannides CG (1994) Sequence motifs of human HER-2 proto-oncogene important for peptide binding to HLA-A2. Int J Oncol 5: 51–62
Fisk B, Blevins TL, Wherton JT and Ioannides CG (1995) Identification of an immunodominant peptide of HER-2 / neu protoncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181: 2109–2117
Hart DNJ (1997) Dendritic cells: unique leucocyte populations which control the primary immune response. Blood 90: 3245–3287
Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT and Mukherji BH (1996) Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 56: 2479–2483
Kapitanovic S, Rads̆oevic S, Kapitanovic M, Andelinovic Š, Ferencic Z, Tavassoli M, Rimorac D, Sonicki Z, Spaventi s Š, Pavelic K and Spaventi R (1997) The expression of p185HER-2 / neu correlates with the stage of diseases and survival in colorectal cancer. Gastroenterology 112: 1103–1113
Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E and Rosenberg SA (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180: 347–352
Kawashima I, Tsai V, Southwood S, Takesako K, Sette A and Celis E (1999) Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2 / neu by primary in vitro immunization with peptide pulsed dendritic cells. Cancer Res 59: 431–435
Kondo A, Sidney J, Southwood S, Del Guercio MF, Appella E, Sakamoto H, Celis E, Grey HM, Chesnut RW, Kubo RT and Sette A (1995) Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. J Immunol 155: 4307–4312
Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, Appella E, Sekikawa T, Matsumoto Y and Kiessling R (1998) Identification of HER2 / neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic lymphocytes. Int J Cancer 78: 202–208
Kubo RT, Sette A, Grey HM, Appella E, Sakaguchi K, Zhu NZ, Arnott D, Sherman N, Shabanowitz J, Michel H, Bodnar WM, Davis TA and Hunt DF (1994) Definition of specific peptide motifs for four major HLA-A alleles. J Immunol 152: 3913–3924
Lönn U, Lönn S, Nilsson B and Stenkvist B (1996) Prognostic significance of c- erb-B2 amplification in fine needle biopsies of breast cancer patients not operated at diagnosis. Breast Cancer Res and Treat 39: 213–220
Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D and Lyerly HK (1999) Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59: 56–58
Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergin MT, Ozols J, Meehan J and Mauri F (1995) Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed antologous antigen presenting cells. Proc Natl Acad Sci USA 92: 8078–8082
Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G and Schadendorf D (1998) Vaccination of melanoma patients with peptideor tumor lysate-pulsed dendritic cells. Nature Med 3: 328–332
Nukaya I, Yasumoto M, Iwasaki T, Ideno M, Sette A, Celis E, Takesako K and Kato I (1999) Identification of HLA-A24 epitope peptide of carcinoembryonic antigen that induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer 80: 92–97
Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I and Eberlein TJ (1995) Breast and ovarian cancer specific cytotoxic T lymphocytes recognize the same HER2 / neu-derived peptide. Proc Natl Acad Sci USA 92: 432–436
Reeves ME, Royal RE, Lam JS, Rosenberg SA and Hwu P (1996) Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 56: 5672–5677
Riddel SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson I, Manley SA, Lupton SD, Overell RW, Retnolds TC, Corey L and Greenberg PD (1996) T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Med 2: 216–223
Romani N, Gruner S, Brang D, Kämpgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM and Schuler G (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180: 83–93
Rosenbeg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudey ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH and White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 4: 321–327
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF (1989) Studies of the HER-2 / neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712
Tsai CM, Yu D, Chang KT, Wu LH, Peng RP, Ibrahim NK and Hung MC (1995) Enhanced chemoresistance by elevation of p185neulevels in HER-2 / neu-transfected human lung cancer cells. J Natl Cancer Inst 87: 682–684
Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A and Celis E (1997) Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol 158: 1796–1802
Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM and Schlom J (1995) Generation of human cytotoxic T cell specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87: 982–990
van der Bruggen P, Traversari C, Chomez P, Lurquin C, De-Plaen E and Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643–1647
Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED and Riddel SR (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow transfer of T-cell clones from the donor. N Engl J Med 333: 1038–1044
Ward RL, Hawkins NJ, Coomber D and Disis ML (1999) Antibody immunity to the HER-2 / neu oncogene protein in patients with colorectal cancer. Hum Immun 60: 510–515
Williams TM, Weiner DB, Greene MI and Maguire HC, Jr (1991) Expression of c-erb-B2 in human pancreatic adenocarcinomas. Pathobiology 59: 46–52
Xia W, Lau YK, Zhang HZ, Liu AR, Li L, Kiyokawa N, Clayman GL, Katz RL and Hung MC (1997) Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Can Res 3: 3–9
Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T and Toyoshima K (1986) Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319: 230–234
Yoshino I, Peoples GE, Goedegebuure PS, Maziarz R and Eberlein TJ (1994) Association of HER2 / neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 152: 2393–2400
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Tanaka, H., Tsunoda, T., Nukaya, I. et al. Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2 / neu: possible immunotherapy for colorectal carcinomas. Br J Cancer 84, 94–99 (2001). https://doi.org/10.1054/bjoc.2000.1547
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1547
Keywords
This article is cited by
-
P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma
Cancer Immunology, Immunotherapy (2014)
-
Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs
Cancer Immunology, Immunotherapy (2006)
-
Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition
Breast Cancer Research (2001)